Qiaomei M. Jin

Nanjing, 210028, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Optimization of covalent pan-fibroblast growth factor receptor inhibitors for treating solid tumors.

Optimization of covalent pan-fibroblast growth factor receptor inhibitors for treating solid tumors.

Journal: European journal of medicinal chemistry

Published: July 06, 2026

ERRATUM: Paris polyphylla Suppresses Proliferation and Vasculogenic Mimicry of Human Osteosarcoma Cells and Inhibits Tumor Growth In Vivo.

ERRATUM: Paris polyphylla Suppresses Proliferation and Vasculogenic Mimicry of Human Osteosarcoma Cells and Inhibits Tumor Growth In Vivo.

Journal: The American journal of Chinese medicine

Published: April 12, 2026

Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy.

Discovery of pyrido[3,2-d]pyrimidin-6(5H)-one derivatives as checkpoint kinase 1 (CHK1) inhibitors with potent antitumor efficacy.

Journal: European journal of medicinal chemistry

Published: January 21, 2024

Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Discovery and Structural Optimization of Novel Quinolone Derivatives as Potent Irreversible Pan-Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Journal: Journal of medicinal chemistry

Published: June 19, 2023

Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.

Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: May 10, 2023

Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor.

Rational design of 4-((6-phenoxypyrimidin-4-yl)amino)-N-(4-(piperazin-1-yl)phenyl)-1H-pyrazole-3-carboxamide (LT-540-717) as orally bioavailable FLT3 inhibitor.

Journal: European journal of medicinal chemistry

Published: March 16, 2023

Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.

Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer.

Journal: European journal of medicinal chemistry

Published: February 19, 2023

Rhizoma Paridis saponins suppresses vasculogenic mimicry formation and metastasis in osteosarcoma through regulating miR-520d-3p/MIG-7 axis.

Rhizoma Paridis saponins suppresses vasculogenic mimicry formation and metastasis in osteosarcoma through regulating miR-520d-3p/MIG-7 axis.

Journal: Journal of pharmacological sciences

Published: June 07, 2022

Target identification and occupancy measurement of necrosis avid agent rhein using bioorthogonal chemistry-enabling probes.

Target identification and occupancy measurement of necrosis avid agent rhein using bioorthogonal chemistry-enabling probes.

Journal: RSC advances

Published: May 05, 2022

Publisher Correction: Development of Duramycin-Based Molecular Probes for Cell Death Imaging.

Publisher Correction: Development of Duramycin-Based Molecular Probes for Cell Death Imaging.

Journal: Molecular imaging and biology

Published: February 23, 2022

Development of Duramycin-Based Molecular Probes for Cell Death Imaging.

Development of Duramycin-Based Molecular Probes for Cell Death Imaging.

Journal: Molecular imaging and biology

Published: October 09, 2021

Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.

Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.

Journal: Bioorganic & medicinal chemistry

Published: August 19, 2020

Showing 1-12 of 41

Last Updated: 09/26/2026